**Author details**

*Translational Research in Cancer*

**6. Conclusions**

we can validate and trust.

**Acknowledgements**

**Conflict of interest**

The authors declare no conflict of interest.

CA 180803.

intercompare with other trials for outcome analysis. This will be true in all adult and pediatric oncology subtypes. We are learning more each day about responsedirected therapies and the relationship of response and disease progression relative to biomarkers. The informatics tools will need to be robust to accommodate this element of data exchange and evaluation. Digital pathology will play an increasingly important role including capture of profiles that are identified to date in a manner similar to oncotype for breast cancer. Tissue will need to be stored for the biomarker not yet identified. Digital capture makes identified objects inexhaustible while tissue is exhaustible, hence the reason we need to store and protect this invaluable resource. Radiation therapy treatment plans will need to be fused with images that define targets and correlate to images that review the pattern of failure. It will be through these mechanisms we will all mature in our understanding of disease

Enterprise-level function of comprehensive clinical trial datasets is closer to reality than it has been in the past. The quality of the dataset will significantly influence the quality of our understanding of the applied information and how we use clinical information moving forward. Efforts need to be made to optimize existing datasets in the NCTN and industry to help move knowledge forward in a manner

processes and the success/failure of our applied therapies [23, 24].

**182**

Thomas J. FitzGerald1 \*, Maryann Bishop-Jodoin1 , Fran Laurie1 , Richard Hanusik1 , Matthew Iandoli1 , Kathryn Karolczuk1 , Sandra Kessel1 , Fred Prior2 , Joel Saltz<sup>3</sup> , Ashish Sharma4 , Michael Knopp5 , Mark Rosen6 , Ying Xiao6 , David Followill7 , Jeff Michalski8 , Ameer Elaimy<sup>9</sup> , James Shen9 , Peter Lee9 , Maria Giulia Cicchetti1 and Janaki Moni1


\*Address all correspondence to: tjfitzgerald@qarc.org

© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
